CryoLife Stock

$30.51

1.10% yesterday

NYSE, Jul 18, 10:00 pm CET

ISIN

US2289031005

Symbol

AORT

Reports

Quarter | Annual

Index

NYSE Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

CryoLife Stock price

$30.49

+11.94 64.37% 5Y

NYSE, Closing price Fri, Jul 18 2025

-0.36 1.17%

ISIN

US2289031005

Symbol

AORT

Reports

Quarter | Annual

Index

NYSE Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$1.3b

Enterprise Value

$1.6b

Net debt

$280.7m

Cash

$37.7m

Shares outstanding

42.7m

Valuation (TTM | estimate)

P/E

negative | 275.0

P/S

3.3 | 3.0

EV/Sales

4.1 | 3.7

EV/FCF

negative

P/B

4.4

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$390.1m | $435.9m

EBITDA

$37.0m | $87.6m

EBIT

$21.1m | $30.1m

Net Income

$-21.4m | $4.8m

Free Cash Flow

$-440.0k

Growth (TTM | estimate)

Revenue

5.9% | 12.2%

EBITDA

-5.2% | 58.3%

EBIT

-9.3% | -22.7%

Net Income

-123.0% | 135.9%

Free Cash Flow

-104.1%

Financial Health

Equity Ratio

35.0%

Return on Equity

-4.8%

ROCE

2.9%

ROIC

2.7%

Debt/Equity

1.1

EPS

$-0.5

FCF per Share

$0.0

Short interest

4.0%

Employees

Rev per Employee

$240.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

CryoLife Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a CryoLife forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a CryoLife forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from CryoLife

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	390 390	6% 6% 100%
- Direct Costs	141 141	8% 8% 36%
Gross Profit	249 249	5% 5% 64%
- Selling and Administrative Expenses	187 187	9% 9% 48%
- Research and Development Expense	28 28	1% 1% 7%
EBITDA	37 37	5% 5% 9%
- Depreciation and Amortization	16 16	1% 1% 4%
EBIT (Operating Income) EBIT	21 21	9% 9% 5%
Net Profit	-21 -21	123% 123% -5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

CryoLife Stock News

Neutral

GlobeNewsWire

●

5 days ago

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Artivion, Inc. Customers Whose Data May Have Been Compromised

NEWTOWN, Pa., July 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Artivion, Inc. (“Artivion”).

Neutral

PRNewsWire

●

about 2 months ago

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel.

Neutral

PRNewsWire

●

about 2 months ago

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the...

More CryoLife News

Company Profile

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Head office	United States
CEO	James Mackin
Employees	1,600
Founded	1984
Website	artivion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now